التفاصيل البيبلوغرافية
| العنوان: |
OA14.05 5-Year Survival of Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With PD-L1 Tumor Proportion Score |
| المؤلفون: |
Gadgeel, Shirish M, RodrÃguez-Abreu, D., Halmos, B., Garassino, M. C, Kurata, T., Cheng, Y., Jensen, E., Shamoun, M., Rajagopalan, K., Paz-Ares, L. |
| المصدر: |
Hematology/Oncology Meeting Abstracts |
| بيانات النشر: |
Henry Ford Health Scholarly Commons |
| سنة النشر: |
2023 |
| المجموعة: |
Henry Ford Health System Scholarly Commons |
| مصطلحات موضوعية: |
carboplatin, cisplatin, endogenous compound, epidermal growth factor receptor, paclitaxel, pembrolizumab, pemetrexed, placebo, programmed death 1 ligand 1, unclassified drug, adult, cancer chemotherapy, cancer patient, cancer survival, China, clinical trial, conference abstract, controlled study, drug safety, drug therapy, female, first-line treatment, follow up, gene expression, health care quality, histology, histopathology, human, human tissue, Japan |
| الوصف: |
Introduction: Pembrolizumab plus chemotherapy significantly improves OS and PFS in patients with previously untreated metastatic NSCLC without EGFR or ALK alterations irrespective of PD-L1 tumor proportion score (TPS). We present 5-year outcomes from a pooled analysis of phase 3 trials of pembrolizumab plus chemotherapy in patients with previously untreated metastatic NSCLC with PD-L1 TPS <1%. Methods: This pooled analysis included individual patient data from the KEYNOTE-189 global (NCT02578680; data cutoff March 8, 2022) and Japan extension (NCT03950674; data cutoff February 7, 2023) studies of metastatic nonsquamous NSCLC without EGFR or ALK alterations and the KEYNOTE-407 global (NCT02775435; data cutoff February 23, 2022) and China extension (NCT03875092; data cutoff February 10, 2023) studies of metastatic squamous NSCLC. In KEYNOTE-189, patients received pembrolizumab or placebo plus pemetrexed and cisplatin or carboplatin; in KEYNOTE-407, patients received pembrolizumab or placebo plus carboplatin and paclitaxel or nab-paclitaxel. PD-L1 expression was centrally assessed using PD-L1 IHC 22C3 pharmDX (Agilent Technologies, Carpinteria, CA). Tumor response was assessed per RECIST version 1.1 by blinded independent central review (BICR). Efficacy was evaluated in the intention-to-treat population and safety in the as-treated population. Analyses were performed post hoc and are descriptive only. Results: Among 442 patients with PD-L1 TPS <1% included in this analysis, 255 (57.7%) received pembrolizumab plus chemotherapy and 187 (42.3%) received chemotherapy alone. Baseline characteristics were similar across treatment groups except for tumor histology; 111 patients (43.5%) in the pembrolizumab plus chemotherapy group and 119 (63.6%) in the chemotherapy alone group had squamous tumors. Median time from randomization to data cutoff was 60.7 (range, 49.9‒72.0) months. OS, PFS, ORR, and PFS2 were improved with pembrolizumab plus chemotherapy versus chemotherapy alone (Table). Treatment-related AEs ... |
| نوع الوثيقة: |
text |
| اللغة: |
unknown |
| العلاقة: |
https://scholarlycommons.henryford.com/hematologyoncology_mtgabstracts/162Test; http://sfxhosted.exlibrisgroup.com/hfhs?sid=EMBASE&issn=15561380&id=doi:10.1016%2Fj.jtho.2023.09.078&atitle=OA14.05+5-Year+Survival+of+Pembrolizumab+Plus+Chemotherapy+for+Metastatic+NSCLC+With+PD-L1+Tumor+Proportion+Score+%3C1%25&stitle=J.+Thorac.+Oncol.&title=Journal+of+Thoracic+Oncology&volume=18&issue=11&spage=S77&epage=S78&aulast=Gadgeel&aufirst=S.&auinit=S.&aufull=Gadgeel+S.&coden=&isbn=&pages=S77-S78&date=2023&auinit1=S&auinitmTest= |
| الإتاحة: |
https://scholarlycommons.henryford.com/hematologyoncology_mtgabstracts/162Test |
| رقم الانضمام: |
edsbas.4AE936A3 |
| قاعدة البيانات: |
BASE |
